S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:MTP

Biodexa Pharmaceuticals (MTP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.29
$3.22
52-Week Range
N/A
Volume
164,300 shs
Average Volume
57,354 shs
Market Capitalization
$6.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MTP stock logo

About Biodexa Pharmaceuticals Stock (NASDAQ:MTP)

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

MTP Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
BDRX Biodexa Pharmaceuticals Plc
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Why Is Midatech Pharma (BDRX) Stock Up 64% Today?
BIOAF: Merger with Midatech Pharma
MTP Midatech Pharma plc
Midatech Pharma PLC Announces ADR Ratio Change
Midatech Pharma PLC News
See More Headlines
Receive MTP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MTP
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$800,000.00
Book Value
$5.67 per share

Miscellaneous

Free Float
21,595,000
Market Cap
$6.18 million
Optionable
Not Optionable
Beta
2.29
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Stephen Anthony Stamp
    Chief Executive Officer, CFO, Secretary & Director
  • Dmitry Zamoryakhin
    Chief Scientific Officer
  • Dan Palmer
    Vice President-Technology
  • Steve Ellul
    Vice President-Business Development
  • Fiona Sharp
    Group Financial Controller

MTP Stock Analysis - Frequently Asked Questions

When did Biodexa Pharmaceuticals' stock split?

Biodexa Pharmaceuticals shares reverse split before market open on Monday, March 27th 2023. The 1-4 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Biodexa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biodexa Pharmaceuticals investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

This page (NASDAQ:MTP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners